Pharmacodynamic enhancement of the anti-platelet antibody Fab abciximab by site-specific pegylation

References

• Avramis V, Sencer S, Periclou A, Sather H, Bostrom B, Cohen L, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 2002; 99: 1986–994.
   PubMed Web of Science ®Google Scholar
• Goodson R J, Katre N V. Site-directed pegylation of recom- binant Interleukin-2 at its glycosylation site. Biotechnology 1990; 8: 343–6.
   PubMedGoogle Scholar
• Gupta S K, Pittenger A L, Swan S K, Marbury T C, Tobillo E, Batra V, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002; 42: 1109–15.
   PubMed Web of Science ®Google Scholar
• Chapman A P, Antoniw P, Spitali M, West S, Stephens S, King D J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999; 17: 780–3.
   PubMed Web of Science ®Google Scholar
• Leong S R, DeForge L, Presta L, Gonzalez T, Fan A, Reichert M, et al. Adapting pharamacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation. Cytokine 2001; 16: 106–19.
   PubMed Web of Science ®Google Scholar
• Choy E H S, Hazleman B, Smith M, Moss K, Lisi L, Scott DG I, et al. Efficacy of a novel pegylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 2002; 41: 1133–7.
   PubMed Web of Science ®Google Scholar
• EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New Engl J Med 1994; 330: 956–61.
   PubMed Web of Science ®Google Scholar
• EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. New Engl J Med 1997; 336: 1689–96.
   PubMed Web of Science ®Google Scholar
• EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coro- nary stenting with use of platelet glycoprotein-IIb/IIIa block- ade. Lancet 1998; 352: 87–92.
   PubMed Web of Science ®Google Scholar
• CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429–35.
   PubMed Web of Science ®Google Scholar
• Martin P, Papayannopoulou T. HEL Cells: A new human erythroleukemia cell line with spontaneous and induced globin expression. Science 1982; 216: 1233–5.
   Google Scholar
• Nisonoff A, Wissler F C, Lipman L N. Properties of the major component of a peptic digest of rabbit antibody. Science 1960; 132: 1770–1.
   PubMed Web of Science ®Google Scholar
• Mascelli M A, Lance E T, Damaraju L, Wagner C L, Weisman H F, Jordan R E. Pharmcodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibi- tion with gradual recovery from GPIIb/IIIa receptor blockade. Circulation 1998; 97: 1680–8.
   PubMed Web of Science ®Google Scholar
• Christopoulos C, Mackie I, Lahiri I, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagulation Fibrinolysis 1993; 4: 729–37.
   PubMed Web of Science ®Google Scholar
• Coller, B S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa Complex. J Clin Invest. 1985; 76: 101–8.
   PubMed Web of Science ®Google Scholar
• Tam S H, Sassoli P M, Jordan R E, Nakada M T. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and aVb3 Integrins. Circulation 1998; 98: 1085–91.
   PubMed Web of Science ®Google Scholar
• Kleiman N S, Raizner A E, Jordan R E, Wang A L, Nortan D, Mace K F, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor- activation peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995; 26: 1665–71.
   PubMed Web of Science ®Google Scholar
• Tcheng J E, Ellis S G, George B S, Kereiakes D J, Kleiman N S, Talley J T, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757–64.
   PubMed Web of Science ®Google Scholar
• Jakubowski J A, Jordan R, Weisman H F. Current antiplatelet therapy. In: Uprichard A C G, Gallagher K P, eds. Handbook of Experimental Pharmacology. Berlin: Springer, 1999; 175–208.
   Google Scholar
• Jordan R E, Wagner C L, Mascelli M A, Treacy G, Nedelman M A, Woody J N, et al. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody frag- ment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA, ed. Adhesion Receptors as Therapeutic Targets. London: CRC Press 1996; 281–30.
   Google Scholar
• Colburn W A. Specific antibodies and Fab fragments to alter the pharmacokinetics and reverse the pharmacologic toxico- logic effects of drugs. Drug Metab Rev 1980; 11: 223–62.
   PubMed Web of Science ®Google Scholar
• Knight D M, Wagner C, Jordan R E, McAleer M F, DeRita R, Fass D N, et al. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramat- ically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995; 32: 1271–81.
   PubMed Web of Science ®Google Scholar
• White J G, Clawson C C. The surface-connected canilicular system of blood platelets–a fenestrated membrane system. Am J Pathol 1980; 101: 353–64.
   PubMed Web of Science ®Google Scholar
• Hartwig, J H. Platelet Structure. In: Michelson AD, ed. Platelets. Boston, MA: Academic Press 2002; 37–52.
   Google Scholar
• Coller B S, Scudder L E, Beer J, Gold H K, Folts J D, Cavagnaro J, et al. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991; 614: 193–213.
   PubMed Web of Science ®Google Scholar
• Dery J P, Braden G A, Lincoff A M, Kereiakes D J, Browne K, Little T, George B S, Sane D C, Cines D B, Effron M B, Mascelli M A, Langrall M A, Damaraju L, Barnathan E S, Tcheng J E, on behalf of the ReoPro Readministration Registry Investigators, Abciximab Readministration: Final Results of the ReoPro® Readministration Registry. Am Heart J accepted for publication.
   Google Scholar
• Fahdi I E, Saucedo J F, Hennebry T, Ghani M, Sadanandan S, Garza-Arreola L. Incidence and time course of thrombocyto- penia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Am J Cardiology 2004; 93: 453–455.
   PubMed Web of Science ®Google Scholar
• Curtis B R, Swyers J, Divgi A, McFarland J G, Aster R H. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99: 2054–59.
   PubMed Web of Science ®Google Scholar